Suraksha Diagnostic Limited has informed the Exchange regarding appointment/re-appointment of Internal Auditor and Cost Auditor for the financial year 2026-27.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported strong FY2026 results with standalone revenue of ₹300.68 crore, up 21% from ₹249.10 crore in FY2025. Standalone profit after tax stood at ₹34.06 crore versus ₹33.44 crore. Consolidated revenue reached ₹310.41 crore with PAT of ₹31.40 crore. EPS (consolidated) improved to ₹6.18 from ₹5.97. The Board recommended a dividend of ₹0.50 per share (25% on face value ₹2) for FY2025-26, the first dividend since FY2023-24 when it was nil. Record date is August 26, 2026, with AGM on September 2, 2026. The company also appointed new internal auditor (M/s. Suresh Surana & Associates LLP) and reappointed cost auditor (M/s. S Chhaparia & Associates) for FY2026-27. Auditors issued an unmodified opinion on the financial statements.
Positive signal for shareholders with revenue growth of 21% and a dividend announcement after a gap year. The unmodified audit opinion confirms financial reliability. However, investors should note the disputed amount of ₹392.20 lakhs in a step-down subsidiary involving the Government of Meghalaya.